New national guideline sets out best practices for treating opioid addiction

March 5, 2018, Canadian Medical Association Journal
Credit: CC0 Public Domain

A new Canadian guideline for managing opioid use disorders lays out the optimal strategies for the treatment of opioid addiction, including recommending opioid agonist treatment with buprenorphine-naloxone as the preferred first-line treatment. The guideline, published in CMAJ (Canadian Medical Association Journal), was created for a wide range of health care providers to address an urgent need for evidence-based treatment of opioid use causing overdoses and death.

"Opioid use disorder is a public health emergency nationwide and this guideline provides a blueprint for health practitioners to step up and provide evidence-based care," says Dr. Julie Bruneau lead author of the pan-Canadian guideline group and a physician at the Centre hospitalier de l'Université de Montréal.

In 2016, the rate of opioid-related deaths in Canada was 7.9 per 100 000 (a total of 2861 deaths), and the number of deaths continues to increase. The affecting both Canada and the United States is fuelled by a combination of overprescribing as well as the influx of highly potent illegal synthetic opioids, such as illicitly manufactured fentanyl.

"Traditionally, resources for the treatment of opioid addiction have been scarce, and guidelines outlining best practices and practices to avoid have been lacking," says Dr. Evan Wood, senior author and director of the BC Centre on Substance Use at St. Paul's Hospital and the University of British Columbia.

To address the traditional gaps in knowledge in this area, the guideline aims to provide Canadian professionals and health authorities with national clinical practice recommendations for treating opioid use disorder. The review panel included 43 health care practitioners with broad experience who are part of the Canadian Institutes of Health Research's Canadian Research Initiative in Substance Misuse (CRISM). The guideline group also involved people with opioid use disorder experience, and considered patient values and preferences in developing its recommendations.

Key recommendations:

  • Start opioid agonist treatment with buprenorphine-naloxone whenever possible to reduce risk of toxicity, illness and death
  • In people who respond poorly to buprenorphine-naloxone, consider transitioning to methadone treatment
  • Start opioid agonist treatment with methadone when buprenorphine-naloxone is not the preferred option
  • In people who respond well to methadone and who want simpler treatment, consider transitioning to buprenorphine-naloxone
  • In patients who do not respond to the above therapies, consider slow-release oral morphine, prescribed as daily witnessed doses
  • Avoid withdrawal management alone without transition to long-term treatment to reduce risk of relapse and death.

Opioid agonist treatment with buprenorphine-naloxone is recommended as first-line treatment because of its better safety record, including lower risk of overdose and lower risk of breathing suppression; ease of use, especially in rural and remote areas where daily witnessed ingestion is not practical; dosing flexibility; and milder withdrawal symptoms if stopping treatment, making it a better option for people with milder opioid dependence.

Beyond recommending best practices, like the use of buprenorphine-naloxone as first-line treatment whenever possible, the guideline also identifies how certain common practices in the Canadian health care system should be avoided—specifically, how offering withdrawal management as an isolated strategy for the treatment of opioid use disorder actually increases rates of overdose.

"With these recommendations laid out, there is an urgent need for health systems to look at the historical gaps in care and invest in providing timely and evidence-based treatment, says Dr. Bruneau, who is also a professor in the Faculty of Medicine at Université de Montréal. "By encouraging physicians to work alongside their patients to identify the safest, most effective approach first, these new guidelines ensure the best science and evidence are integrated into care."

Opioid use disorder is often a chronic, relapsing condition associated with increased morbidity and risk of death. However, with appropriate treatment and follow-up, individuals can reach sustained long-term remission.

For the full list of recommendations, see Table 1 in the guideline.

In a related commentary, Drs. Joseph Donroe and Jeanette Tetrault from the Yale University School of Medicine, New Haven, Connecticut, write "this national guideline describing the pharmacologic management of opioid use disorder is timely and needed to address the expanding epidemic of opioid use disorder and overdose. Importantly, the guideline is geared toward front-line providers, who are vitally important to decrease the existing treatment gap."

Next steps include increasing education of health care providers about recognizing and managing opioid use disorders and chronic pain, reducing stigma associated with substance use disorders, expanding prescribing access to opioid agonists and expanding access to harm reduction services.

The guideline was funded through the Canadian Research Initiative in Substance Misuse (CRISM), a network funded by the Canadian Institutes of Health Research (CIHR).

"Management of use disorders: a national clinical practice guideline" is published March 5, 2018.

Explore further: Slow-release oral morphine could expand options for treating opioid abuse

More information: Julie Bruneau et al. Management of opioid use disorders: a national clinical practice guideline, Canadian Medical Association Journal (2018). DOI: 10.1503/cmaj.170958

Joseph H. Donroe et al. Narrowing the treatment gap in managing opioid use disorder, Canadian Medical Association Journal (2018). DOI: 10.1503/cmaj.180209

Related Stories

Slow-release oral morphine could expand options for treating opioid abuse

December 25, 2017
Slow-release oral Morphine (SROM) has emerged as a promising candidate for oral opioid agonist therapy. However, more research is needed before it can be incorporated into U.S. treatment guidelines. A commentary from the ...

Study finds opportunity to increase opioid dependence treatment in Ontario jails

February 15, 2018
A study from McMaster University suggests more can be done to improve access to and delivery of opioid dependence treatment in adult correctional facilities in Ontario.

Study examines opioid agonist therapy use in Medicare patients

July 20, 2016
Few Medicare enrollees appear to be receiving buprenorphine-naloxone, the only opioid agonist therapy for opioid addiction available through Medicare Part D prescription drug coverage, according to a study published online ...

Medications to treat opioid use disorders—new guideline from the American Society of Addiction Medicine

September 24, 2015
Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments. New evidence-based recommendations ...

Clinical trial looks at tramadol for opioid withdrawal

July 12, 2017
A randomized clinical trial published by JAMA Psychiatry compared tramadol extended-release with clonidine and buprenorphine for the management of opioid withdrawal symptoms in patients with opioid use disorder in a residential ...

New opioid guideline for chronic non-cancer pain focuses on preventing harm

May 8, 2017
A new guideline for prescribing opioids for people with chronic non-cancer pain is aimed at helping health care professionals in Canada limit use of these addictive and potentially lethal drugs. The guideline, published in ...

Recommended for you

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

Prescription drug monitoring programs may have negative unintended consequences

May 7, 2018
Prescription drug monitoring programs (PDMPs) are a key component of the President's Prescription Drug Abuse Prevention Plan and considered a critical tool for reducing prescription opioid-related illness and death. The results ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.